5^th June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Canada's Largest Cardiac Centre Adopts Steriwave

Ottawa Heart Institute Adopts Ondine's Steriwave^® Nasal Photodisinfection as Standard of Care for Cardiac Surgeries

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that the University of Ottawa Heart Institute ("OHI"), one of Canada's leading cardiac care centres, has adopted Steriwave^® nasal photodisinfection as a standard of care for all cardiac surgeries. This decision reinforces OHI's commitment to patient safety and innovation in infection prevention.

OHI is Canada's largest and foremost cardiovascular health centre, recognized internationally for its world-class expertise in cardiac care, research, and education. Serving as a major referral centre for Eastern Ontario, OHI provides advanced cardiac surgery, interventional cardiology, and comprehensive patient care to thousands of patients each year. The Institute is renowned for its pioneering research, innovative clinical programs, and commitment to patient safety and outcomes. OHI's multidisciplinary teams are dedicated to advancing the prevention, diagnosis, and treatment of heart disease, making OHI a leader in cardiovascular innovation both in Canada and globally.

The Ottawa Heart Institute joins a growing number of leading hospitals, including Vancouver General Hospital, The Ottawa Hospital, Mazankowski Alberta Heart Institute, University of Alberta Hospital and other major Canadian and UK institutions that have successfully implemented Steriwave nasal decolonization in their pre-surgical protocols. Clinical deployments have demonstrated significant reductions in SSI (surgical site infection) rates, further validating Steriwave as an effective and innovative solution for infection control.

Carolyn Cross, CEO of Ondine Biomedical:

"We are extremely pleased to be supporting the Ottawa Heart Institute's efforts to address multidrug resistance and enhance their patient protection protocols. By adopting Steriwave as standard of care, OHI is once again demonstrating its leadership in clinical excellence and its commitment to staying at the forefront of infection prevention. We are honoured to partner with such a forward-thinking institution, and we look forward to supporting OHI as they continue to set new benchmarks in patient protection and antimicrobial stewardship."

Steriwave photodisinfection is a light-activated, non-antibiotic antimicrobial therapy that rapidly eradicates all types of nasal pathogens associated with surgical site infections without generating resistance or relying on patient compliance. Unlike currently used antimicrobials, Steriwave provides full-spectrum nasal decolonization in minutes, offering a powerful new tool in the fight against healthcare-associated infections and antibiotic resistance. Steriwave continues to gain recognition with a proven track record of improving surgical outcomes and reducing healthcare costs.

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.